CANPAIN Feasibility Study Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients

NCT05288010 | Unknown Phase 3

• 1 other identifier: IRAS 304548
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The CANPAIN study has been devised to evaluate the efficacy and safety of a defined cannabis based medicinal product (CBMP) delivered by inhalation to patients with non cancer chronic pain attending a private clinic. CANPAIN is a pragmatic non-randomised, non-blinded real-world trial of the safety, tolerability and effectiveness of a cannabis based medicinal product (CBMP) for the treatment of chronic non-cancer pain compared against matched controls receiving standard of care pain management. CANPAIN will run for 3 years with a minimal planned sample size of 5000 participants per group who have completed at least 12 months of treatment. CANPAIN will be an MHRA and REC approved study. (See Appendix 1 of the Feasibility Study for the full draft protocol of the CANPAIN Study) Prior to commencing the CANPAIN study, the sponsor proposes to conduct a feasibility study. This study will aid in establishing likely rates of patient recruitment, duration of participant enrolment in the study, the demographic and geographic spread of patients, patient acceptability of data collection and identify any issues with technological and drug delivery logistics.

Conditions

Chronic Pain

Keywords

Cannabis; Whole Flower Cannabis

Outcome Measures

Primary Outcomes (10)

• Recruitment Experience

  Assess rate of recruitment to the clinic. Measure time taken to recruit the first 100 patients from time of first patient in study until end of study. This will be measured using an electronic patient record which will record the date each patient entered and left the study.

  3 months

• Duration of Time in Study

  Assess the number/proportion of patients that cease treatment at the Clinic. Measure the average time all patients remained in the study. This will be measured using an electronic patient record which will record the date each patient entered and left the study.

  3 months

• Questionnaire Compliance

  Assess the number of patients that complete all questionnaires required. Measure the percentage of patients that completed all questionnaires required as part of the study.

  3 months

• Safety Questionnaire Results

  Assess the number of patients that experience safety issues. Report the number of patients that recorded a score of 5 or more on the NRS tolerability questionnaire, in any of the safety questions.

  3 months

• Medication Logistics

  Assess the timeliness and efficiency of CBMP delivery to the patient. Record average time taken for medication to reach patients after prescription has been completed using the shipping data from the pharmacy and the receipt date by the patient from the courier.

  3 months

• Device Experience

  Assess the presence of issues with the usability of the inhalation device. Record number of patients that had issues with using the device from the comments questionnaire and from emails and phone calls to the study site.

  3 months

• Onboarding Experience

  Ease of onboarding. Report from comments questionnaire and email and phone interactions with study site number of patients that had difficulties with registering with the clinic and entering into the study.

  3 months

• Questionnaire Logistics and Satisfaction

  Ease of answering questionnaires. Record the number of patients that had problems with accessing or filling in the questionnaires from comments questionnaire and email and phone interactions with the study site.

  3 months

• Questionnaire Fatigue

  Evidence of questionnaire fatigue. Report on the number of people that did not complete all questionnaires or did not complete them correctly or who complained about the number of questionnaires and questions in each questionnaire from the comments form and emails and phone calls to study site.

  3 months

• Patient Satisfaction with Service

  Patients are required to fill out a Feedback Questionnaire which has a number of questions within it regards the service provided. Patients are required to rate the answers to these questions as Excellent, Good, Fair or Poor. The percentage of patients recording Excellent, Good, Fair and Poor will be calculated and tabulated and reported on.

  3 months

Secondary Outcomes (2)

• Demographic

  3 months

• Conversion to Registration

  3 months

Study Arms (1)

Active Group

OTHER

Patients of the clinic receiving cannabis treatment for non cancer chronic pain, who have been invited to join the study and have agreed and consented to join study.

Combination Product: Cannabis

Interventions

Cannabis COMBINATION_PRODUCT

The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.

Active Group

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A consented patient at the clinic;
• Male or female 18-85 years old;
• Diagnosed with chronic non-cancer pain;
• Is currently receiving standard of care but still has pain, has completed standard of care pain treatment, does not want standard of care treatment, or standard of care is contraindicated. An inadequate response is defined as the subject receiving standard analgesic agents and still has pain, has unpleasant side effects or wishes to reduce their intake of standard of care analgesic agents, e.g. a subject receiving opioids who wishes to dose reduce in light of the "opioid crisis";
• Despite being on or having received standard of care and has still pain (\>3 on the Pain NRS); and
• Signed and dated consent form from the patient.

You may not qualify if:

• Pregnant or lactating females or females who are planning a pregnancy during the study;
• Positive pregnancy test at time of joining the clinic;
• Major organ failure, renal, lung or liver failure;
• Participants having active liver disease or unexplained persistent elevation of serum transaminases \> 3 times the upper limit of normal;
• Participants with a creatinine clearance \< 60mL/min;
• History of cardiac or respiratory failure;
• History of recent myocardial infarction or poorly controlled ischaemic heart disease;
• Severe respiratory disease (e.g., GOLD 3 for COPD or asthmatics requiring high doses of oral corticosteroids);
• History or presence of alcohol or substance abuse, including analgesics used as standard of care;
• Participation in a clinical trial of an investigational medicinal product;
• With any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder disorders other than depression associated with their underlying condition;
• Known hypersensitivity to cannabis or allergy to cannabis or CBMP; and
• Currently taking cannabis and does not agree to a 3 week wash out period.

Sponsors & Collaborators

• Harley Street (CPC) Limited: lead

Study Sites (1)

LVL Health

London, W1G 9HH, United Kingdom

Location

MeSH Terms

Conditions

Chronic Pain; Marijuana Abuse

Interventions

nabiximols

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Shaw Sorooshian, MB ChB

  LVL Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Treatment with cannabis via an inhalation device in addition to standard of care chronic pain treatment.

Study Record Dates

• First Submitted: February 22, 2022
• First Posted: March 18, 2022
• Study Start: March 15, 2022
• Primary Completion: June 15, 2022
• Study Completion: June 30, 2022
• Last Updated: March 18, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)